摘要
目的:评价CA153、CA125和VEGF对乳腺癌患者手术前后手术治疗效果以及预后评价的临床意义。方法:收集我院2007年1月到2009年1月乳腺外科收治的女性浸润性导管癌患者131例,比较所有患者术前以及术后3月随访时血清CA153、CA125和VEGF值的变化。结果:四期患者手术前血清CA153、CA125和VEGF亦均高于正常,手术后复查均恢复至正常范围,四组患者手术前后血清CA153、CA125以及VEGF比较差异均有统计学意义(P<0.05),Ⅲ和Ⅳ期血清VEGF、CA125和CA153值均明显高于Ⅰ和Ⅱ期(P<0.05),Ⅰ和Ⅱ期、Ⅲ和Ⅳ期之间血清VEGF、CA125和CA153值比较差异无统计学意义(P>0.05)。结论:CA153、CA125和VEGF检测对于判断乳腺癌的分期有一定作用,能有效评价手术治疗效果判断患者是否复发,以及对肿瘤发展的阶段也具有临床指导意义。
Objective：To evaluate the prognosis of clinical significance of CA 153,CA 125 and VEGF in breast cancer patients before and after surgical treatment.Methods：From January 2007 to January 2009 in our hospital the female breast surgery treated patients with invasive ductal carcinoma of 131 patients, comparing all patients before and 3 months after follow-up, serum CA153,CA125 and VEGF values change. Results：The four patients with preoperative serum CA153,CAI25 and VEGF always make higher than normal after surgery and recovery to normal review, four groups of patients before and after surgery serum CA153,CA125 and VEGF were statistically significant differences （P 〈0.05 ）,Ⅲ and IV of serum VEGF,CA125 and CA153 were significantly higher than I andⅡ （P〈0.05）,I and Ⅱ ,Ⅲ and IV between the serum VEGF, CA 125 and CA 153 was no difference between the value of significance （P〉0.05）.Conclusion：CA 153,CA 125 and VEGF in breast cancer staging test for judging has a certain effect, it can effectively evaluate the surgical treatment to determine whether patients relapse and the stage of tumor development also has clinical significance.
出处
《中国医药导刊》
2011年第5期791-792,共2页
Chinese Journal of Medicinal Guide
